1.
Degener Neurol Neuromuscul Dis
; 9: 103-107, 2019.
Artículo
en Inglés
| MEDLINE
| ID: mdl-31686946
RESUMEN
Friedreich's Ataxia (FRDA) is a devastating and progressive ataxia, marked by mitochondrial dysfunction and oxidative stress. Nrf2 activators such as omaveloxolone (Omav) modulate antioxidative mechanisms, and thus may be viable therapeutic agents in FRDA.